Many liver diseases are associated with endocrine disorders, including nonalcoholic fatty liver disease (NAFLD), autoimmune hepatitis and primary biliary cirrhosis. NAFLD is the most common liver disorder worldwide and its rising prevalence mirrors that of obesity and type 2 diabetes. Thyroid disorders are often associated with hepatic alterations. Chronic liver disease can impair menstruation and fertility. In addition, patients with diabetes have a higher prevalence of significant liver fibrosis and enhanced risk of disease progression to cirrhosis and hepatocellular carcinoma. Management of these disorders should consider the relationship between the liver and the endocrine system, in order to address all manifestations and complications.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Liver Disorders Content
Achieving best practice management of primary biliary cholangitis, now and in the future
Watch two specialists in autoimmune liver disease discuss best practice in the management of primary biliary cholangitis, including assessing emerging therapies and personalization of care.
- Describe the recommendations for diagnosis and management of patients with primary biliary cholangitis
- Evaluate emerging treatment options for patients with primary biliary cholangitis
- Review and implement individualized management for patients with primary biliary cholangitis
Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
touchREVIEWS in Endocrinology. 2022;18(2):148-55 DOI: https://doi.org/10.17925/EE.2022.18.2.148
Non-alcoholic fatty liver disease (NAFLD), which impacts an estimated 25% of the world’s adult population,1–3 is the principal cause of chronic liver disease globally. NAFLD as a whole represents a pathological spectrum of liver injury, spanning from simple steatosis to non-alcoholic steatohepatitis (NASH) and liver fibrosis, with an evolutionary course to cirrhosis and risk of hepatocellular […]
Peter Ferenci, EASL ILC 2022: Wilson’s disease – diagnosis and treatment
Wilson’s disease is a rare, genetic disorder characterized by the accumulation of excess copper in vital organs such as the liver and brain. Damage caused by the excess copper build-up can lead to symptoms of liver and neurological diseases. In this touchENDOCRINOLOGY interview, we speak with Prof. Peter Ferenci (Medical University of Vienna, Vienna, Austria) […]
Camilla Dalby Hansen, EASL ILC 2022: Non-calorie restricted, low carbohydrate, high fat diet for NAFLD in T2DM
touchENDOCRINOLOGY spoke with Camilla Dably Hansen (Odense Hospital, Denmark) about the findings from the recent 6-month randomised controlled trial investigating the impact of a non-calorie restricted, low carbohydrate, high fat diet on nonalcoholic fatty liver disease (NAFLD) activity score (NAS) and HbA1c in patients with type 2 diabetes (T2DM). The abstract entitled ‘A non-calorie restricted […]
Aleksander Krag, EASL 2022: International Liver Congress Update
We caught up with the European Association for the Study of the Liver (EASL) Vice-Secretary, Prof. Aleksander Krag, to discuss the upcoming International Liver Congress (ILC) and what to expect. At ILC 2022 they will be bringing back face-to-face meetings in a new model, reshaping the scientific programme, offering a fresh experience, merging the very best […]
Donna Cryer, GLI 2022: International NASH Day
Ahead of International NASH Day, we had the pleasure of meeting with the Global Liver Institute Founder, President and Chief Executive Officer Donna Cryer to discuss this year’s theme ‘Stop NASH Now’, and the importance of endocrinologists in the NASH patient journey. Questions How does GLI help support patients and their endocrinologists? (0:28) This year’s […]
Building Equity into the Equation: Stopping NAFLD & NASH in Black Americans
Nonalcoholic steatohepatitis (NASH) has a relatively short history as a recognized health condition. The terminology for NASH and its precursor nonalcoholic fatty liver disease (NAFLD) date back to only the 1980s1. As a young disease, the stakeholders from throughout the field have the opportunity to integrate a health equity perspective into research, diagnosis, and treatment […]
Global Liver Institute Launches Final Nonalcoholic Steatohepatitis (NASH) Externally-Led Patient Focused Drug Development Meeting Outcome Report
To view the full Press Release, please click here. (Washington, DC, Wednesday, March 9, 2022)—Today, Global Liver Institute (GLI) is proud to launch the final NASH Externally-Led Patient Focused Drug Development Meeting Outcome Report. On November 4th 2021, Global Liver Institute led an Externally Led Patient-Focused Drug Development Meeting on NASH. This GLI led EL-PFDD […]
Lise Lotte Gluud, EASD 2021: Effect of Subcutaneous Semaglutide on Features of the Metabolic Syndrome in Patients with Non-alcoholic Steatohepatitis
touchENDOCRINOLOGY caught up with Prof Lise Lotte Gluud (Copenhagen University Hospital, Hvidovre, Denmark) virtually during the EASD Annual Meeting 2021 conference to discuss her study on the effect of subcutaneous semaglutide on features of the metabolic syndrome in patients with non-alcoholic steatohepatitis. Questions 1. Could you give us a brief overview of the association of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!